Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621000696897
Ethics application status
Approved
Date submitted
17/03/2021
Date registered
7/06/2021
Date last updated
13/09/2023
Date data sharing statement initially provided
7/06/2021
Date results information initially provided
13/09/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
To assess if the administration of a clot busting medication (Tenecteplase) administered at the site of the clot in the brain following intravenous administration of the clot busting medication is safe and feasible in patients with acute ischaemic stroke within 4.5 hours of symptom onset.
Query!
Scientific title
Safety and Feasibility of Intravenous Tenecteplase thrombolysis plus Intra-arterial (IA) Tenecteplase thrombolysis in ischaemic stroke patients with medium vessel occlusion (distal M2, 3, 4, ACA, PCA).
Query!
Secondary ID [1]
303724
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MOSS – Medium vessel Occlusion Stroke Study
Query!
Linked study record
N/A
Query!
Health condition
Health condition(s) or problem(s) studied:
Ischaemic stroke
321150
0
Query!
Condition category
Condition code
Stroke
318953
318953
0
0
Query!
Ischaemic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intravenous thrombolysis: Patients will receive intravenous tenecteplase (TNK) 0.25mg/kg (maximum 25mg) administered as a bolus over 10 seconds within 4.5 hours of stroke onset. The dose of the intravenous treatment is individualised (weight dependent).
This will be followed by a digital substraction angiography (DSA) performed by a certified neurointerventionalist within 6 hours of stroke onset. The DSA itself without intervention has usually takes 20 minutes.
Patients will have arterial puncture of the femoral or the radial artery and sheath inserted and cerebral angiography performed under local anaesthesia. If the target lesion is confirmed on angiography to be more suitable for mechanical thrombectomy (depending on the diameter of the target occluded vessel) then a standard thrombectomy will be performed and the patient will be excluded from the study. A guide catheter will be navigated to the proximal artery either Carotid Artery or vertebral artery. A microcatheter will be navigated to the target vessel. The positioning of the microcatheter will be at the discretion of the operator but will ideally be directly in the target occluded vessel. If a target lesion is confirmed on angiography to be unsuitable for standard mechanical thrombectomy then the patient will progress to intra-arterial (IA) administration of TNK 1-3mg via a microcatheter. The dose of the intra-arterial TNK administration will be dependent on radiological evidence of reperfusion of the vessel. It will be administered in 1mg decrements, but not more than 3mg total dose.
This is a one-time treatment with an average duration of 40-60 minutes.
The decision against standard mechanical thrombectomy and for intra-arterial TNK administration within the study is based on the individual's vessel occlusion demonstrated on angiogram. The decision for standard mechanical thrombectomy is an exclusion from the study and the patient will be withdrawn from the study and will receive standard follow up care. The position of the clot and vascular access are influencing this decision. Usually a clot size of 8mm and more will lead to thrombectomy. The mechanical thrombectomy may require the induction of general anaesthesia. Standard mechanical thrombectomy has an intra-procedural risk of vessel rupture due to mechanical manipulation which increases with smaller size of the target vessel. The average duration of a mechanical thrombectomy is 1.5 hours and will be performed by a certified neurointerventinalist.
We will be auditing the study medication use and every procedure performed in accordance to the protocol.
Query!
Intervention code [1]
320332
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
326880
0
Proportion of patients with medium vessel recanalisation on MRI-DWI (diffusion weighted imaging) or CT perfusion without symptomatic intracerebral haemorrhage (sICH) at 24 hrs.
Query!
Assessment method [1]
326880
0
Query!
Timepoint [1]
326880
0
24 hours post treatment
Query!
Secondary outcome [1]
392949
0
Modified Rankin Scale (mRS) score at 3 months
Query!
Assessment method [1]
392949
0
Query!
Timepoint [1]
392949
0
3 months post treatment
Query!
Secondary outcome [2]
392951
0
Proportion of patients recanalised at time of angiography (before IA TNK) demonstrated radiologically by open vessel during angiography
Query!
Assessment method [2]
392951
0
Query!
Timepoint [2]
392951
0
At the conclusion of angiography
Query!
Secondary outcome [3]
394355
0
Proportion of patients reaching NIHSS (National Institutes of Health Stroke Scale) score 0-1 and mRS 0–1 or no change from baseline at 3 months
Query!
Assessment method [3]
394355
0
Query!
Timepoint [3]
394355
0
At the conclusion of study at 3 months
Query!
Secondary outcome [4]
394356
0
mRS 0–2 or no change from baseline at 3 months
Query!
Assessment method [4]
394356
0
Query!
Timepoint [4]
394356
0
3 months post treatment
Query!
Secondary outcome [5]
394357
0
Home time (number of days spent at home up to Day 90) as per patient interview
Query!
Assessment method [5]
394357
0
Query!
Timepoint [5]
394357
0
3 months post treatment
Query!
Secondary outcome [6]
394358
0
Length of stay in hospital as per medical records
Query!
Assessment method [6]
394358
0
Query!
Timepoint [6]
394358
0
At discharge
Query!
Secondary outcome [7]
394359
0
Death due to any cause
Query!
Assessment method [7]
394359
0
Query!
Timepoint [7]
394359
0
3 months post treatment
Query!
Secondary outcome [8]
394360
0
Proportion of patients reaching NIHSS 0-1 at Day 3
Query!
Assessment method [8]
394360
0
Query!
Timepoint [8]
394360
0
Day 3 post treatment
Query!
Secondary outcome [9]
394361
0
Symptomatic intracerebral haemorrhage (sICH) as per radiological scans
Query!
Assessment method [9]
394361
0
Query!
Timepoint [9]
394361
0
Day 3 post treatment
Query!
Secondary outcome [10]
394362
0
Ischaemic core volume at 24hr as per radiological scans (MRI or CT Perfusion)
Query!
Assessment method [10]
394362
0
Query!
Timepoint [10]
394362
0
24 hours post treatment
Query!
Eligibility
Key inclusion criteria
1. Patients presenting with acute ischaemic stroke eligible using standard criteria to receive IV thrombolysis within 4.5 hours of stroke onset.
2. Patient’s age is 18 years or over
3. Intra-arterial clot retrieval treatment can commence (arterial puncture) within 6 hours of stroke onset.
4. Willing to provide written (or oral) informed consent.
Imaging inclusion Criteria
5. Arterial occlusion on CT-Angiogram or MR-Angiogram of distal MCA (middle cerebral artery) branches (M2, 3, 4), ACA (anterior cerebral artery) or PCA (posterior cerebral artery) or corresponding CT-perfusion deficit
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Intracranial haemorrhage (ICH) identified by CT or MRI
2. Rapidly improving symptoms at the discretion of the Investigator.
3. Pre-stroke mRS equal to or greater than 4
4. Contraindication to imaging with contrast agents
5. Any terminal illness such that patient would not be expected to survive more than 1 year.
6. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
7. Pregnant women.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Simon's two-stage design will be used. In the first stage, 5 patients will be accrued. If there are no or one response in these 5 patients, the study will be stopped. Otherwise, 13 additional patients will be accrued for a total of 18. The null hypothesis will be rejected if 7 or more responses are observed in 18 patients.
Dichotomous outcomes will be presented as proportions and 95% confidence limits. Continuous outcomes will be presented as mean (standard deviation) or median (range) as appropriate. Analysis of variance will be used to assess gender-related difference in 3-month mRS. R software will be used for analysis.
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Data collected is being analysed
Query!
Reason for early stopping/withdrawal
Participant recruitment difficulties
Query!
Date of first participant enrolment
Anticipated
21/06/2021
Query!
Actual
3/08/2021
Query!
Date of last participant enrolment
Anticipated
2/06/2023
Query!
Actual
13/07/2022
Query!
Date of last data collection
Anticipated
30/09/2024
Query!
Actual
8/09/2022
Query!
Sample size
Target
18
Query!
Accrual to date
Query!
Final
3
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
18937
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment postcode(s) [1]
33444
0
2065 - St Leonards
Query!
Funding & Sponsors
Funding source category [1]
308132
0
Hospital
Query!
Name [1]
308132
0
Royal North Shore Hospital
Query!
Address [1]
308132
0
Royal North Shore Hospital
Department of Neurology, Clinical Administration 3E
Reserve Road
St Leonards NSW 2065
Query!
Country [1]
308132
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Northern Sydney Local Health District
Query!
Address
Royal North Shore Hospital
Reserve Road
St Leonards NSW 2065
Query!
Country
Australia
Query!
Secondary sponsor category [1]
308893
0
None
Query!
Name [1]
308893
0
Query!
Address [1]
308893
0
Query!
Country [1]
308893
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
308119
0
Northern Sydney Health District Human Research Ethics Committee
Query!
Ethics committee address [1]
308119
0
Kolling Building, Royal North Shore Hospital
Reserve Road
St Leonards NSW 2065
Query!
Ethics committee country [1]
308119
0
Australia
Query!
Date submitted for ethics approval [1]
308119
0
23/11/2020
Query!
Approval date [1]
308119
0
01/02/2021
Query!
Ethics approval number [1]
308119
0
2020/ETH02394
Query!
Summary
Brief summary
This study aims to assess if the administration of a clot busting medication (tenecteplase) administered at the site of the clot in the brain following intravenous administration of the clot busting medication is safe and feasible in patients with acute ischaemic stroke within 4.5 hours of symptom onset.
The approach in our study is to carefully select the patients with disabling strokes within hours of their symptoms commencing. If the clot can be dissolved at this point the damage to the brain can be prevented.
Patients will receive the treatment with a clot busting medication (tenecteplase) shown in multiple trials to be likely more effective and at least as safe in opening up brain vessels compared to the standard medication used. This is followed by an angiography and if the clot is still present and visualised in a medium sized vessel, which is deemed too small to be treated with mechanical removal, a small dose of the same clot busting medication will be administered directly into the clot. (These patients are still at risk of having disabling stroke deficits if the vessel cannot be reopened.)
The administration of a clot busting medication directly at the site of the clot in the brain has been safely tested in multiple trials, but not targeting the specific patient group as in our study.
The participants will be monitored for their immediate stroke symptom outcomes and followed up until three months after their stroke for any disabling effects. We will assess if the participants are able to return to their pre-stroke function and lifestyle.
This is a pilot study including 18 patients with the expectation that it will be followed by a larger trial involving multiple centres comparing this intervention with a group receiving the current standard treatment.
We hypothesise that the administration of a clot busting medication directly into the clot is safe will lead to better outcomes in stroke patients who are not suitable for the standard therapy.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
109602
0
Dr Miriam Priglinger
Query!
Address
109602
0
Royal North Shore Hospital
Department of Neurology
Reserve Road
St Leonards NSW 2065
Query!
Country
109602
0
Australia
Query!
Phone
109602
0
+61 405808879
Query!
Fax
109602
0
+61 2 946 31071
Query!
Email
109602
0
[email protected]
Query!
Contact person for public queries
Name
109603
0
Ms Susan Day
Query!
Address
109603
0
Royal North Shore Hospital
Department of Neurology
Reserve Road
St Leonards NSW 2065
Query!
Country
109603
0
Australia
Query!
Phone
109603
0
+61 2 946 31732
Query!
Fax
109603
0
+61 2 946 31071
Query!
Email
109603
0
[email protected]
Query!
Contact person for scientific queries
Name
109604
0
Dr Miriam Priglinger
Query!
Address
109604
0
Royal North Shore Hospital
Department of Neurology
Reserve Road
St Leonards NSW 2065
Query!
Country
109604
0
Australia
Query!
Phone
109604
0
+61 2 946 31733
Query!
Fax
109604
0
+61 2 946 31071
Query!
Email
109604
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified epidemiological data, imaging findings and intervention results
Query!
When will data be available (start and end dates)?
After publication of our study up until one year after publication
Query!
Available to whom?
On discretion of the principal investigators to researchers who provide a methodically sound proposal
Query!
Available for what types of analyses?
For meta-analyses
Query!
How or where can data be obtained?
By contact to the principal investigator (
[email protected]
)
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
Basic results
No
381636-(Uploaded-15-08-2023-16-04-26)-Basic results summary.docx
Plain language summary
No
All three participants received intra-arterial clo...
[
More Details
]
Documents added automatically
No additional documents have been identified.
Download to PDF